On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies ... a reversible alternative to CRISPR. The collaboration complements Lilly’s ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Without collaboration, the full potential of precision medicine could remain just out of reach. This fragmentation runs deep, spanning researchers, clinicians, pharmaceutical companies ...

Charles R. Goulding and Aaron Rofe reveal how industry leaders like Eli Lilly, Johnson & Johnson, and Roche are going all-in ...

The collaboration between Samsung and LX is expected to create synergy by strengthening the domestic chip fabrication ecosystem. LX Semicon, formerly Silicon Works Co., is a fabless semiconductor ...